Invivo Hx depletion in mouse

Invivo, Hx depletion in mouse models of hemolytic disorders, β-thalassemic mice and phenylhydrazine (PHZ)-treated mice, was associated with heme accumulation and oxidative stress in the heart. Data show that in β-thalassemic mice, low Hx serum level, was associated to increased expression of heme- and oxidative stress responsive genes in the heart (Fig. 6). The same occurred in PHZ-treated mice (Fig. 7). Administration of the anti-oxidant α-tocopherol to PHZ-treated mice normalized the expression of anti-oxidant genes (Fig. 8).
Experimental Design, Materials and Methods
Acknowledgements
Data
Experimental design, materials and methods
Manuscript for the Data in Brief article Table 1A and B. Patients admitted with CAD comprised the largest group (49.0%) of admissions. Acute CAD was the main cause (39.3%) for admission, with patients significantly younger in age (mean age 67.4y), primarily male (69.2%), and had significantly better outcomes (mortality 4.0%) and shorter hospital stays (mean stay 6.7d). The second largest category for admissions was patients with arrhythmias (15.2%). Patients with heart failure (HF) represented 10.0% of admissions. HF patients were significantly older (mean age 75.2y), hospitalized significantly longer (mean stay 12.0d) and had significantly poorer outcomes (mortality 10.5%) than the other types of admission. Valvular disease was the fourth cause of admission (Tables 2 and 3).
Acknowledgements
Data The data presented include the illustrative examples of plaque classification on CCTA (Fig. 1) and measurement of 18F-NaF uptake in coronary atherosclerotic lesions on PET (Fig. 2), and images of a case with a non-calcified coronary plaque detected on CCTA and identified on 18F-NaF PET/non-contrast computed tomography (CT) (Fig. 3).
Experimental design, materials and methods
Conflict of interest
Acknowledgements This study was supported by a Japan Heart Foundation Research Grant, and by a JSPS KAKENHI Grant-in-Aid for Scientific Research (Grant Number 26870395).
Data Summary data for dietary intake of nrf2 keap1 and assessment of neuropsychological and executive function are presented for subjects with phenylketonuria enrolled in a randomized, controlled, crossover trial conducted from November 2010 to July 2015 [1,2]. These data are herein reported for the first time (Tables 1-3). The trial is registered at www.clinicaltrials.gov as NCT01428258 .
Experimental design Thirty subjects with early-treated phenylketonuria, 20 with classical and 10 with a milder or variant form of phenylketonuria, completed the clinical trial [1]. The experimental design was a 2-stage, randomized, controlled, crossover trial where subjects followed their usual low-phenylalanine diet in combination with amino acid medical foods and glycomacropeptide medical foods for 3-weeks each at home (Fig. 1). The protocol included: a one-week baseline period for diet education and orientation to the protocol while consuming the usual amino acid medical foods, the first 3-week dietary treatment with glycomacropeptide medical foods or amino acid medical foods, a 3-week washout period with return to the usual amino acid medical foods, a 1-week baseline period, and lastly the second 3-week dietary treatment with the glycomacropeptide medical foods or amino acid medical foods.
Materials and methods Daily amino acid intake from the whole diet, medical foods, and natural food was calculated from consecutive 3-day food records at the end of the 3-week amino acid medical foods and glycomacropeptide medical foods treatments (Table 1). Amino acid calculations were performed by a Registered Dietitian skilled in standardized diet entry using Food Processor SQL (ESHA, version 10.12.0). Neuropsychological testing to assess executive function, the Delis-Kaplan Executive Function System™ (Pearson Canada Assessment, Inc. Ontario, Canada), and the Cambridge Neuropsychological Test Automated Battery (Cambridge Cognition Ltd, Cambridge, UK) was conducted by research staff trained in the administration of standard psychological assessments under the supervision of a licensed psychologist after following the amino acid medical foods and glycomacropeptide medical foods treatments for 3 weeks (Tables 2-3).